(Q40608454)

22 September 2017

title

Moving disease biology from the lab to the clinic (English)

1 reference

22 September 2017

1 reference

Kenneth C Anderson

1

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

22 September 2017

number of pages

6

1 reference

inferred from page(s)

published in

Cancer

1 reference

22 September 2017

volume

97

1 reference

22 September 2017

issue

3 Suppl

1 reference

22 September 2017

page(s)

796-801

1 reference

22 September 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Multiple Myeloma. Advances in disease biology: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11137

7 January 2021

Identifiers

DOI

10.1002/CNCR.11137

1 reference

release_feasxclah5bm5edxdyyonnod3m

22 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/feasxclah5bm5edxdyyonnod3m

24 November 2022

mapped directly with Wikidata item

1 reference